Manufacturer record
Nestor Pharmaceuticals Limited II: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by Nestor Pharmaceuticals Limited II (Haryana) were declared Not of Standard Quality in September 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: CADC-02, Cefixime Oral Suspension IP Dry Syrup 100mg/5ml (exp Jan 2027). DTL, TVPM (state lab) found it not of standard quality: The Sample does not conform to IP Standards. It fails the tests Water and Assay as per IP as specified in the Laboratory Protocol. Listed in the September 2026 alert.
Records by type
2 records linked to Nestor Pharmaceuticals Limited II in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Cefixime Oral Suspension IP Dry Syrup 100mg/5ml | Batch CADC-02Mfg Feb 2025 · Exp Jan 2027 | The Sample does not conform to IP Standards. It fails the tests Water and Assay as per IP as specified in the Laboratory ProtocolAssay | DTL, TVPMState lab | Sep 2026 |
| Calcium and Vitamin D3 Tablets IP (500 mg +250 IU) (Calcium 500 mg & Vitamin D3 250 IU) | Batch CUTC-250Mfg Dec 2025 · Exp Nov 2027 | The Sample does not conform to IP standards with respect to the test Dissolution.Dissolution | DTL, ThrissurState lab | Sep 2026 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.